SCHEMBL4051244

SCHEMBL4051244

O=C(O)N1CCC(NCCc2ncccc2[N+](=O)[O-])CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 7/20 0.43
MAPT P10636 2/20 0.43
SIGMAR1 Q99720 1/20 0.41
DPP4 P27487 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
DRD4 P21917 1/20 0.40
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
CTSB P07858 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4051782 0.85 GPR119 (0.46) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL1813803 0.84 ALDH1A1 (0.55) ALDH1A1SIGMAR1KDM4EMEN1KMT2A
SCHEMBL1813802 0.84 ALDH1A1 (0.55) ALDH1A1SIGMAR1KDM4EMEN1KMT2A
SCHEMBL4047755 0.83 DRD4 (0.39) SMN1; SMN2ALDH1A1SIGMAR1KDM4EMEN1
SCHEMBL15204675 0.79 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1MAPTSIGMAR1DPP4
SCHEMBL15204677 0.79 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1MAPTSIGMAR1DPP4
SCHEMBL17506440 0.79 ALDH1A1 (0.40) ALDH1A1MAPTSIGMAR1KDM4EMEN1
SCHEMBL2101463 0.75 ALDH1A1 (0.70) SMN1; SMN2ALDH1A1SIGMAR1KDM4EMEN1
SCHEMBL23236018 0.75 DPP4 (0.47) SMN1; SMN2ALDH1A1MAPTSIGMAR1DPP4
SCHEMBL21811036 0.75 DPP4 (0.47) SMN1; SMN2ALDH1A1MAPTSIGMAR1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013214-B1 CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2015-06-24 EP disclosed
EP-2013214-A2 CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS Bristol-Myers Squibb Company (US) 2009-01-14 EP disclosed
US-7470680-B2 Constrained compounds as CGRP-receptor antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-30 US disclosed
WO-2007131020-A2 CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-15 WO disclosed
US-20070259851-A1 CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259851-A1 CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS CALCR, BDKRB2, CALCRL SMN1; SMN2 4233/4885ALDH1A1 3451/4885MAPT 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.